|1.||Field, Hugh J: 6 articles (07/2014 - 08/2007)|
|2.||Suzuki, Hiroshi: 6 articles (04/2013 - 08/2010)|
|3.||Kuchta, Robert D: 5 articles (10/2013 - 07/2004)|
|4.||Chono, Koji: 5 articles (03/2013 - 08/2010)|
|5.||Cheng, Hans H: 4 articles (05/2015 - 06/2014)|
|6.||Dunn, John R: 4 articles (05/2015 - 06/2014)|
|7.||Hildebrandt, Evin: 4 articles (05/2015 - 06/2014)|
|8.||Biswas, Subhajit: 4 articles (07/2014 - 08/2007)|
|9.||Kontani, Toru: 4 articles (03/2013 - 08/2010)|
|10.||Katsumata, Kiyomitsu: 4 articles (03/2013 - 08/2010)|
01/01/2015 - "Helicase-primase as a target of new therapies for herpes simplex virus infections."
07/01/2014 - "Pharmacokinetics-pharmacodynamics of the helicase-primase inhibitor pritelivir following treatment of wild-type or pritelivir-resistant virus infection in a murine herpes simplex virus 1 infection model."
04/24/2014 - "Helicase-primase inhibitor pritelivir for HSV-2 infection."
01/16/2014 - "Pritelivir, an inhibitor of the viral helicase-primase complex, exhibits antiviral activity in vitro and in animal models of herpes simplex virus (HSV) infection. "
01/16/2014 - "Helicase-primase inhibitor pritelivir for HSV-2 infection."
04/01/2013 - "To determine the efficacy of a new helicase-primase inhibitor, ASP2151, for treating herpetic keratitis. "
04/01/2013 - "Efficacy of herpes virus helicase-primase inhibitor, ASP2151, for treating herpes simplex keratitis in mouse model."
02/01/2008 - "Efficacy of a helicase-primase inhibitor in animal models of ocular herpes simplex virus type 1 infection."
|3.||Marek Disease (Marek's Disease)
03/01/2015 - "The Mut UL5-I682R Marek's Disease Virus with a Single Nucleotide Mutation Within the Helicase-Primase Subunit Gene not only Reduces Virulence but also Provides Partial Vaccinal Protection Against Marek's Disease."
05/04/2015 - "Characterizing in vivo stability and potential interactions of a UL5 helicase-primase mutation previously shown to reduce virulence and in vivo replication of Marek's disease virus."
06/01/2014 - "Characterizing the molecular basis of attenuation of Marek's disease virus via in vitro serial passage identifies de novo mutations in the helicase-primase subunit gene UL5 and other candidates associated with reduced virulence."
01/01/2015 - "Addition of a UL5 helicase-primase subunit point mutation eliminates bursal-thymic atrophy of Marek's disease virus ∆Meq recombinant virus but reduces vaccinal protection."
|4.||Herpes Genitalis (Genital Herpes)
07/01/2012 - "Taken together, these results demonstrate that ASP2151 inhibits the replication of HSV clinical isolates more potently than ACV, and HSV resistant to this novel helicase-primase inhibitor as well as ACV may not easily emerge in short-term treatment for recurrent genital herpes patients."
07/01/2012 - "Susceptibility of herpes simplex virus isolated from genital herpes lesions to ASP2151, a novel helicase-primase inhibitor."
01/01/2011 - "Effect of ASP2151, a herpesvirus helicase-primase inhibitor, in a guinea pig model of genital herpes."
01/01/2007 - "Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease."
|5.||Human Influenza (Influenza)
11/15/2013 - "In this second part of "Dancing with antivirals as chemical formulae" I will focus on a number of chemical compounds that in the last few years have elicited more than common attraction from a commercial viewpoint: (i) favipiravir (T-705), as it is active against influenza, but also several other RNA viruses; (ii) neuraminidase inhibitors such as zanamivir and oseltamivir; (iii) peramivir and laninamivir octanoate, which might be effective against influenza virus following a single (intravenous or inhalation) administration; (iv) sofosbuvir, the (anticipated) cornerstone for the interferon-free therapy of HCV infections; (v) combinations of DAAs (direct antiviral agents) to achieve, in no time, a sustained virus response (SVR) against HCV infection; (vi) HIV protease inhibitors, the latest and most promising being darunavir; (vii) the integrase inhibitors (INIs) (raltegravir, elvitegravir, dolutegravir), representing a new dimension in the anti-HIV armamentarium; (viii), a new class of helicase primase inhibitors (HPIs) that may exceed acyclovir and the other anti-herpes compounds in both potency and safety; (ix) CMX-001, as the latest of Dr. Antonín Holý's legacy for its activity against poxviruses and CMV infections, and (x) noroviruses for which the ideal antiviral compounds are still awaited for. "
|3.||Antiviral Agents (Antivirals)
|4.||BILS 45 BS
|5.||cidofovir hexadecyloxypropyl ester
|9.||HIV Protease Inhibitors